| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2010 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EXELIXIS INC | 45 | Q2 2024 | 88.9% |
| ISHARES MSCI INDIA ETF | 33 | Q2 2024 | 6.2% |
| WISDOMTREE INDIA EARNINGS FUND | 33 | Q2 2024 | 5.5% |
| ALKERMES PLC | 31 | Q4 2020 | 62.6% |
| ESPERION THERAPEUTICS INC | 29 | Q2 2024 | 34.4% |
| VIVUS INC | 15 | Q4 2016 | 21.3% |
| CELLDEX THERAPEUTICS | 14 | Q2 2020 | 2.7% |
| PROSHARES ULTRAPRO SHORT S&P500 | 4 | Q4 2017 | 3.8% |
| PROSHARES ULTRASHORT S&P500 | 4 | Q4 2017 | 3.0% |
| PROSHARES ULTRASHORT S&P 500 ETF | 3 | Q3 2019 | 0.8% |
View Meditor Group Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Esperion Therapeutics, Inc. | January 03, 2024 | 3,791,300 | 3.3% |
| EXELIXIS, INC. | April 09, 2019 | 15,001,073 | 5.0% |
| VIVUS INC | December 19, 2012 | 5,002,896 | 5.0% |
| VIVUS INC | March 21, 2012 | 6,177,500 | 6.3% |
| VION PHARMACEUTICALS INC | February 15, 2008 | 5,736,200 | 7.6% |
| CYPRESS BIOSCIENCE INC | September 26, 2007 | 1,864,645 | 5.0% |
| ONYX PHARMACEUTICALS INC | September 12, 2007 | 2,627,800 | 4.8% |
| ACUSPHERE INC | July 26, 2007 | 1,839,421 | 4.0% |
| NOVACEA INC | June 11, 2007 | 800,000 | 3.4% |
| ATHEROGENICS INC | May 02, 2007 | 1,361,800 | 3.5% |
View Meditor Group Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-12 |
| 13F-HR | 2024-07-22 |
| 13F-HR | 2024-04-11 |
| 13F-HR | 2024-01-04 |
| SC 13G/A | 2024-01-03 |
| 13F-HR | 2023-10-31 |
| 13F-HR | 2023-07-25 |
| 13F-HR | 2023-04-10 |
| 13F-HR | 2023-01-05 |
| SC 13G/A | 2023-01-04 |
View Meditor Group Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.